Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Addition of Tukysa to standard first-line maintenance therapy for patients with HER2-positive breast cancer offers an opportunity to prolong time to disease progression or death. (Angus Liu/Questex) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results